D. Doval Et Al. , "Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can," 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium , vol.75, San-Antonio, Northern Mariana Islands, 2014
Doval, D. Et Al. 2014. Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can. 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium , (San-Antonio, Northern Mariana Islands).
Doval, D., Cinieri, S., Bozcuk, H., Pierga, J., Altundag, K., Wang, X., ... Gupta, S.(2014). Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can . 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands
Doval, Dinesh Et Al. "Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can," 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 2014
Doval, Dinesh Et Al. "Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can." 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium , San-Antonio, Northern Mariana Islands, 2014
Doval, D. Et Al. (2014) . "Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can." 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium , San-Antonio, Northern Mariana Islands.
@conferencepaper{conferencepaper, author={Dinesh Doval Et Al. }, title={Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can}, congress name={37th Annual CTRC-AACR San Antonio Breast Cancer Symposium}, city={San-Antonio}, country={Northern Mariana Islands}, year={2014}}